A Milestone Week For COVID-Affected Trials
Executive Summary
Back-to-back US FDA advisory committee reviews of applications for a novel RSV antibody and a breakthrough Alzheimer’s therapy are a quietly remarkable testament to the resilience of drug development – and the flexibility of FDA – through the COVID pandemic.